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Abstract 
Among the most heinous, and unfortunately common, crimes known to human society are rape 
and child molestation. Recidivism rates for offenders of these crimes are extremely high. 
Treatment of perpetrators of these crimes is of great consequence to mental health professionals, 
policymakers and the general public.  Unfortunately, the traditional treatments for rehabilitation, 
including cognitive-behavioral therapy and SSRIs, have shown only minimal success rates and 
incarceration is expensive for the state. One proposed alternative is chemical castration. This 
paper reviews ethical considerations regarding the practice of chemical castration for sex 
offenders.  
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An Ethical Analysis of the Chemical Castration of Sex Offenders 
The Crime and its Impact 
Sexual assault is sexual contact involving forcible (actual or threatened) coercion or 
involving an individual who is not able to give consent (e.g. under the influence, a child). Legal 
statutes define sexual assault in varying degrees. Legal definitions of sexual assault differ by 
country and state; however, for New York State, offenders may be charged with rape (used when 
penetration is involved), sexual abuse (does not require penetration, only touching, either directly 
or through clothing) or sodomy (penetration of areas other than the vagina) in the first, second or 
third degrees. All of the above charges are considered felonies.  
The prevalence of sexual assault depends on its definition, which varies among studies. 
In 2004, the Uniform Crime Reports indicated 94,635 reports of women being forcibly raped. 
The U.S. Department of Justice (1998) estimated a lifetime prevalence of 1 in 3 women 
experiencing rape or attempted rape. The majority occurred in metropolitan areas and over a 
third occurred in the South. This data reflects only reported crimes. Factors which affect rates of 
reported rapes include community education, service availability, social support, victim age and 
the relationship between the victim and the assailant. Studies have estimated that for each 
woman who reports to the authorities four to fifteen more rapes occur but remain unreported 
(Hanson & Gidycz, 1993; Koss, Gidycz & Wisniewski, 1987). Russell and Howell (1983) 
calculated a 46 percent probability that a woman will be raped in her lifetime based on a survey 
of 930 women. 
Physical injury is relatively rare, occurring in about one-third of cases (Ledray, 1999), 
and increases in likelihood in cases involving older victims and male victims and in cases of 
stranger rape (Bownes, O’Gorman & Saters, 1991; Ledray, 1998; Petrak & Claydon, 1995; 
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Tintinelli & Hoelzer, 1985). Rape victims’ risk for STIs is also low; 6-12% for gonorrhea, 4-17% 
for Chlamydia, 0.5-3% for syphilis and <1% for HIV infection as estimated by the Centers for 
Disease Control (1993) and the risk of pregnancy is 2-4% (Yuzpe, Smith & Rademaker, 1982). 
Indirect health risks may affect more victims than immediate physical injury. Psychological 
distress is common. Rape victims are at greater risk for anxiety, depression and post-traumatic 
stress disorder (PTSD) (Frazier, 1997). Between a third and half of victims of sexual assault 
report contemplating suicide (Ellis, Atkeson & Calhoun, 1981; Resnick, Jordan, Girelli, Kotsis 
Hutter, & Marhoefer-Dvorak, 1988) and up to twenty percent of victims attempt suicide 
(Kilpatrick, Saunders, Veronon, Best, & Von, 1987). Stress caused by sexual assault can result in 
a suppressed immune system and greater risk of disease. It can also result in an increase in self-
injurious behaviors like substance abuse and/or eating disorders, increased sexual activity with 
multiple partners leading to increased exposure to disease, or emotional difficulties manifested as 
physical symptoms (Cohen & Williamson, 1991; Felitti, 1991; Golding, 1994; Koss, Woodruff, 
& Koss, 1990; Ledray, 1994). Another common problem following sexual assault is sexual 
dysfunction, including avoidance, loss of interest, loss of pleasure, painful intercourse and fear 
(Abel & Rouleau, 1995; Burgess & Homstrom, 1979, Kimmerling & Calhoun, 1994; Koss, 
1993). 
Like sexual assault committed against adults, the prevalence varies based on the 
definition of abuse. In cases of childhood abuse, the definition of childhood also varies among 
studies. The age group most affected by sexual violence is adolescents and young adults. Of 
female rape victims in the United States, 54% are younger than 18 (Tjaden & Thoennes, 1998). 
Data from a study by Muram and colleagues (1995) indicates that, compared to adult victims, 
adolescents are significantly less likely to have been physically injured or to have had a weapon 
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used against them and are more likely to have experienced alcohol- or drug-facilitated assault, 
suggesting that sex offenders may coerce adolescent victims more easily than adults without 
weapons or physical injury.  
Children who are sexually abused commonly experience fear, PTSD, poor sex esteem 
and display sexual inappropriateness (Kendall-Tacket, Williams & Finkelhor, 1993; 
McConaghy, 1998). Long term sexual symptoms resemble that of adult victims (Leonard & 
Follette, 2002; Loeb, Williams, Carmona, Rivkin, Wyatt, Chin, & Asuan-O’Brian, 2002). 
Childhood sexual abuse has also been linked to psychopathology in adulthood (Chu & Dill, 
1990; Fossati, Madeddu & Maffei, 1999). 
Victims of these crimes experience extreme trauma and may suffer chronically as a 
result. Families and friends are also significantly impacted by sexual violence. In addition to the 
pain suffered by victims as a result of psychological and physical difficulties resulting from an 
assault, treatment also places a burden on health care systems as well.  
The Perpetrators 
The majority of rapists are male. Ward and colleagues (1997) found that rapists are more 
likely than non-offenders to come from a low socioeconomic background (though date rapists 
are more likely to come from a middle- or upper-class background) and have a criminal record. 
FBI Uniform Crime Reports indicate that, of the rapists with police records, perpetrators tend to 
be under 25. Hudson & Ward (1997) further found that they are more likely to have a history of 
sexual abuse, a childhood violent home environment, and inconsistent caregiving in childhood.  
Rapists are exemplified by impulsivity, quick tempers, insensitivity to social cues and 
limited intimate relationships (Giotakos, Markianos, Vaidakis, & Christodoulou, 2004). They 
also display hostile masculinity, emotional detachment and predatory personalities (LeVay & 
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Valente, 2003). They show limited understanding of the feelings and intentions of others, for 
example, reading friendly behaviors as sexual and the inability to read negative cues (Ward et al., 
1997; Emmers-Sommer, Allen, Bourhis, Sahlstein, Laskowski, Falato, Ackerman, Erian, 
Barringer, &Weiner, 2004). However, Lisak & Miller (2002) found that, on average, rapists had 
more consensual sex than their peers. 
Abel & Rouleau (1990) reported that some rapists are also affected by a paraphilia. Of 
the participants in their study, 28% met some criteria for exhibitionism; 18%, for voyeurism. The 
American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders 
defines pedophilia as acting on or impairment caused by “recurring, intense sexually arousing 
fantasies, urges or behaviors involving sexual activating with a prepubescent child or children 
(generally age 13 or younger)”. Though some pedophiles display no preference for the sex of 
their victims, most are either exclusively heterosexual or homosexual. Homosexual pedophiles 
abuse a greater number of victims than heterosexual pedophiles (Blanchard, Barbaree, Bogaert, 
Dickey, Klassen, Kuban, & Zucker, 2000; Cohen & Galynker, 2002). 
Lee and colleagues (2002) reported that, compared to rapists, pedophiles were more 
likely to have experienced childhood sexual abuse. Common among men with pedophilia is an 
idealization of traits associated with childhood like innocence (Cohen & Galynker, 2002). 
Pedophiles often believe that sexual contact is not harmful to children or that children desire 
sexual contact, sometimes to the point of believing that the victim initiated sexual contact 
(Cohen & Galynker, 2002; Segal & Stermac, 1990). 
Sex offenders display atypical arousal patterns. Like normal non-offending men, most 
rapists find depictions of consensual sex to be arousing; however, the offender subset of the male 
population was also aroused by depictions of sex involving an unwilling victim (Abel & 
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Rouleau, 1990). Among pedophiles, those with female victims show greater or equal arousal for 
picture of nude or semi-nude girls than similar pictures of adult women (Seto, Lalumiere & 
Kuban, 1999). 
Recidivism Rates 
 In 1994, seven-year-old Megan Kanka was raped and strangled by a neighbor, who had 
previously been convicted of child molestation. Public outrage following her murder led to the 
passage of Megan’s Law by the State of New Jersey, which required the post-release registration 
of convicted sex offenders and community notification of sex offenders moving into the 
neighborhood. Since then, many other states have passed Megan’s Laws. While these laws have 
been controversial, they speak to the recognition of high recidivism rates for sex offenders. 
Indeed, recidivism rates for offenders of these crimes are extremely high. In a study of 
1,882 men, 63% of those who had committed rape had committed more than one, with an 
average of 5.8 rapes each (Lisak & Miller, 2002). In a longitudinal study of over 300 sex 
offenders, Langevin and colleagues (2004) found that over half were charged with one or more 
sexual offences. Some types of offenders have higher rates of recidivism than others; generally 
the highest are those with deviant sexual preferences, such as exhibitionists, sadists, and 
pedophiles (Dickey, Nussbaum, Chevolleau & Davidson, 2002; Langevin et al., 2004). Aging 
reduces recidivism rates (Dickey et al, 2002; Hanson, 2002). 
Treatment Options 
Incarceration  
As previously noted, many sex offenders go undetected because reports are not made. 
Many cases are not brought to trial by the state and still more are decided in favor of the 
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defendant. This paper deals with offenders who have been convicted of their crime. Among men 
convicted of rape, approximately one-third do not serve jail time (LeVay & Valente, 2006). 
Those who are imprisoned face risks in prison because of the nature of their crime. Sex 
offenders must often be separated from the mainstream population to protect them from 
harassment, physical injury, rape and murder committed by other prisoners. While for the 
protection of prisoners who have committed sex crimes, segregation can result in limited access 
to prison facilities and feelings of fear.  
While ideally the penal system should provide rehabilitation, in practice, jail time is 
punishment rather than treatment. Incarceration prevents reoffending only for the length of the 
prison sentence. McGuire (2002) concluded that punishment and deterrence methods are 
ineffective in preventing future offences.  
Cognitive-Behavioral  
 The current psychotherapies employed involve modifying patterns of arousal, thinking 
patterns and behavior to reduce reoffending. In aversion therapy, deviant sexual arousal patterns 
are altered by pairing a paraphilic stimulus with mild electric shock, foul odor or induced nausea 
at peak arousal (Quinsey & Earls, 1990). Positive reinforcement is also used to replace the sex 
offender’s typical pattern of arousal with acceptable stimuli (i.e. consenting adults) by having the 
subject masturbate as they would usually, then switch to imagining an appropriate fantasy right 
before orgasm (Maletzky, 2002; Earls & Quinsey, 1985; Quinsey & Earls, 1990). Another 
technique, cognitive restructuring, aims to adjust the subjects’ sexual views. Cognitive 
restructuring involves challenging the cognitive distortions (such as believing that women enjoy 
being raped or that children can consent or initiate sexual activity) of the sex offender (Maletzky, 
2002). Treatment of sex offenders may also include social skills training to teach offenders how 
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to correctly interpret social situations as non-sexual and how to appropriately respond (Maletzky, 
2002; McFall, 1990) Reports on the efficacy of these therapies outside the laboratory setting 
show mixed results – some report modest outcomes, others report virtually no difference 
between offenders who received treatment and those who did not (Alexander, 1999; Maletzky & 
Steinhauser, 2002; Marshall, Jones, Ward, Johnston, Barbaree, 1991). 
SSRIs 
 The selective serotonin reuptake inhibitor (SSRI) fluoxetine has been successfully used to 
reduce deviant urges in a number of paraphilias including pedophilia (Perilstein, Lipper & 
Friedman, 1991). SSRIs have also been tested in patients with hypersexuality as well as one case 
study of a rapist (Kafka, 1991; Kafka & Prentky, 1992). In this population, reduced sexual 
interest was reported.  
 The recent success of SSRI use to treat paraphilias and hypersexuality has generated 
questions about the possible relation of these diseases to obsessive-compulsive disorders (Stein, 
Hollander, Anthony, Schneifer, Fallon & Liebowitz, 1992)). Those with paraphilias may be 
suffering from impulse control disorders. In this conceptualization of the disease, deviant sexual 
fantasies are the compulsion and acting on these deviant sexual urges is the compulsive behavior. 
Further research is needed in this area. 
Surgical Castration 
 Throughout history, surgical castration has been used for a variety of purposes (Stelizer, 
1997). In some cultures, female living quarters were served and guarded by eunuchs. In the 
1700s, the practice of castration was used to maintain the high singing voices of male choir 
members past puberty. The eugenics movement in the early 20
th
 century promoted sterilization 
of criminals and the mentally ill. As a punishment for rape, castration has been used for centuries 
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(Heim & Hursch, 1979). Surgical castration for sex offenders was the legal standard of care in 
many European countries, including Denmark, Germany, Norway, Finland, Estonia, Iceland, 
Latvia and Sweden, for much of the twentieth century and was also legal in many U.S. states. 
 Bilateral orchiectomy, that is, the excision of both testes, results in significantly 
decreased sexual drive and activity; however, in some cases, erectile response is still possible 
(Aass, Grunfeld, & Kaalhus, 1993; Van Basten, Van Driel, & Hoeskstra, 1999; Van Basten, Van 
Driel, & Jonker- Pool, 1997). This invasive surgical procedure is permanent. Suppression of 
libido and arousal and erectile dysfunction are experienced across the board, not just in deviant 
sexual behaviors and urges. Sexual recidivism among surgically castrated felons is remarkably 
low - about 1% of subjects (Sturup, 1972). In other studies, those who did reoffend were being 
treated with testosterone to reduce the symptoms associated with castration (Hansen, 1991; 
Hansen & Lykke-Olesen, 1997). 
 Side effects of the surgery can be quite severe. In addition to the sex-related physical 
changes, there are health risks beyond those normally associated with surgery. Most patients 
undergoing surgical castration reported reduced body hair and slack and flabby skin. Many 
experience enlarged breasts. Castrated sex offenders experienced heart and respiratory problems, 
chronic pain, hot flashes, night sweats, and vertigo (Langeluddeke, 1963). 
  Surgical castration has been rejected by most courts in the United States on the basis that 
it qualifies as cruel and unusual punishment.  Especially since the advent of a non-invasive 
alternative – chemical castration, surgical castration has been abandoned as the standard 
treatment in the U.S. In cases where the chemical castration may pose significant health risks or 
treatment-resistant cases, surgical castration is still sometimes performed on sex offenders. 
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Chemical Castration 
 Chemical castration is not castration, per se, in that there is no cutting involved. This 
homonotherapy reduces circulating levels of testosterone by chemical means. Androgens - 
testosterone and dihydrotestosterone- are critical in the regulation of male sexuality (Rubinow & 
Schmidt, 1996). Erection and ejaculation are both influenced by testosterone levels (Bradford. 
2001). Conversely, testosterone levels increase with sexual activity (Jannini et al, 1999). 
Testosterone is also linked to aggression. Testosterone levels have been correlated with violent 
crime (Ehrenkranz, Bliss, & Sheard, 1974; Kreuz & Rose, 1972; Virkkunen, Rawlings, et al., 
1994), but the precise relationship between aggression and testosterone is unclear (Volavka, 
1995). Steroid antiandrogen drugs reduce sex drive by blocking androgen receptors. 
Medroxyprogesterone Acetate 
 Medroxyprogesterone acetate (MPA), also known by brand names Clinovir, Cycrin, 
Depo-Provera, and  Hystron, is the hormone used for chemical castration in the United States.  
MPA first came to the market to treat gynecological problems in females. The Food and Drug 
Administration (FDA) withdrew MPA from the market in 1978. MPA is available outside the 
U.S. as birth control; however, the FDA has never approved it for this use. Heller, Laidlaw, 
Hervey and Nelson (1958) first reported that progestational compounds decreased testicular size 
and suppressed completely male libido. MPA was first used with sex offenders by Money (1970) 
in conjunction with behavioral treatments.  
 MPA reduces testosterone production by inhibiting gonadotropin secretion (Gijs & 
Gooren, 1996). MPA accelerates testosterone metabolism in the liver leading to lower circulating 
levels of testosterone (Southren, Gordon, Vittek, Altman, 1977). MPA is administered as an 
intramuscular injection of about 400 milligrams weekly.  (Blumer & Migeon, 1975; Gagne, 
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1981; Money, 1970). In one study, MPA was also delivered orally in 60mg daily doses 
(Gottesman & Schubert, 1993).  
 Effects are seen within two to three weeks of starting a course of MPA (Gagne, 1981). In 
a study of 48 participants, Gagne (1981) reported forty participants who positively responded to 
MPA and that all participants experienced lowered sexual fantasy, arousal and urges (particularly 
masturbation). MPA leads to significant reduction in time spent engaging in sexual fantasies, 
number of morning erections, number of ejaculations, frequency of paraphilic behavior and 
circulating testosterone levels (Gottesman & Schubert, 1993). Berlin & Meinecke (1981) treated 
20 patients and reported a 15% relapse rate. Risk factors for relapse include elevated baseline 
testosterone, previous head injury, and substance abuse (Meyer, Collier, Emory, 1992). 
 Side effects reported by patients varied in severity, but common side effects included 
fatigue following injections, headache, nausea, hot flashes, and insomnia. Physical changes as a 
result of taking MPA included gynecomastia and weight gain (Gagne, 1981; Meyer, Collier & 
Emory, 1992). More serious side effects seen in a smaller percentage of patients included 
phlebitis, hypertension, gastrointestinal complaints, gallstones, and diabetes (Kravitz, Haywood, 
& Kelly, 1995; Meyer, Collier, Emory, 1992). 
Cyproterone Acetate 
 Cyproterone acetate (CPA), marketed under the names Androcur, Cyprone, Cyprostat, 
and Dianette, is not officially approved in the United States, but is used in Canada, the United 
Kingdom and Germany. Comparative studies of MPA and CPA are difficult because the drugs 
are not available in the same countries.  
In their seminal study on the clinical uses of CPA, Laschet & Laschet (1971) observed 
significantly reduced or eliminated sexual drive, erections and orgasms in 100 sexually deviant 
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male participants. CPA decreases testosterone production by competitive inhibition of 
testosterone and dihydrotestosterone in androgen receptors. CPA is available in pill form given 
daily and as an intramuscular injection given every two weeks. Laschet & Laschet (1971) used 
either 100mg oral doses daily or 300mg intramuscularly every two weeks. Currently, oral 
dosages range from 50-200mg daily and intramuscular dosages range from 200-400mg each 
week or every other week.  
Mothes, Lehnert, Samimi and Ufer (1997) found that CPA decreases sex drive within one 
to two weeks. In a study by Bancroft and colleagues (1974), patients receiving CPA scored lower 
on written measures of sexual interest and sexual activity. Like MPA, CPA suppresses sexual 
fantasties, libido, number of morning erections, number of ejaculations and spermatogenesis 
(Neumann & Schleusener, 1980). Bradford & Pawlak (1993) reported patients treated with CPA 
showed a reduction in anxiety and irritability. Side effects of CPA include depression, 
nightmares, headaches, gynecomastia, weight gain, muscular cramps, dyspepsia, gallstones, 
increased blood sugar levels, diabetes mellitus and liver dysfunction (Bancroft et al, 1974; 
Cremonocini, Viginati, & Libroia, 1976; Gijs & Gooren, 1996; Neuman, 1977). 
Ethical Considerations  
Public Costs and Benefits 
A utilitarian argument which sought to obtain the most good for the greatest amount of 
people favors chemical castration for repeat sex offenders.  As previously stated, sex offenders 
pose a severe threat to public well-being. Most offenders have many victims and the cost to the 
victim is quite high. Curbing the deviant behaviors of sex offenders would be beneficial in 
ensuring the security of many individuals. Sexual assault can have serious physical and mental 
health outcomes for victims. In addition to the pain and suffering of victims and family 
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members, treating survivors of sexual assault can be expensive.  Stopping sexual assaults results 
in significant financial benefits as well. Resources that would have gone to treating victims of 
sexual assault could be used for numerous other beneficial programs. 
While there are other options to prevent sex offenders from reoffending, the option of 
chemical castration for policymakers with a utilitarian perspective is attractive because of the 
financial savings it provides. The cost of incarceration to the taxpayer is extremely high. For 
each U.S. resident, state prisons spend $204 yearly. According to figures put out by the 
Department of Justice (2001), the average annual cost per state inmate is $22, 650 in state 
operated facilities and $22,632 per inmate in federal prisons. Comparatively, each injection of 
Depo-Provera costs between $35-75. Even taking the highest figure for medication and the 
lowest figure for incarceration costs, the yearly cost to furnish felons with Depo-Provera is more 
than eighteen thousand dollars per felon. Again, some of the resources currently provided to the 
penal system could be diverted to other programs. 
The benefits of chemical castration in terms of the public good seem to outweigh the 
costs. The security of the public needs to be maintained and, to do this, certain rights of the few 
need to be compromised. Yet incarceration satisfies the goal of keeping the public safe while 
limiting fewer rights than chemical castration, despite being more expensive to the taxpayer. 
Compliance Issues 
 Furthermore, chemical castration is not a fool-proof way to achieve public safety.  In 
certain experimental studies MPA and CPA have been administered by the patient in pill form 
daily. On top of the fact that this is a drug with unpleasant side effect being taking by a possibly 
not-so-willing population, anyone who takes daily medication can testify to how easy it is to 
forget to take your pills.  
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When used by the justice system, the drug used for chemical castration in the United 
States is dispensed via intramuscular injection by a medical professional rather than self-
medication, but compliance cannot be ensured by this method of administration either. An 
injection of testosterone can counteract the effect of medroxyprogesterone acetate. Testosterone 
has been used in cancer patients who have undergone a bilateral orchiectomy to limit the sexual 
side effects. As in cases of surgical removal of the testes, testosterone can alter the effects of 
chemical castration as well. Felons seeking to counteract the MPA or CPA can obtain 
testosterone, which is freely available on the black market. 
Problems with compliance counter the utilitarian argument that achieving safety for the 
greatest number of individuals justifies chemical castration. Since even with monitoring 
administration, patients can reverse the effects, it could potentially be a danger to the public if 
sex offenders likely to repeat their crimes were released, especially if the public believed they 
were safe because of the drug being given. In addition to the threat to the public, felons taking 
drugs on the black market might endanger their health as well. Neither the safety of the public 
nor the safety of the criminals could be guaranteed. 
Safety Concerns   
The safety of the antiandrogen drugs themselves is also questionable. Those taking MPA 
or CPA face considerable health risks as a result of the medication. Proponents of chemical 
castration argue that the side effects are comparable to medications used to treat other diseases. 
Every commercial for a prescription drug ends with a long list of side effects that can range from 
minor discomfort to life-threatening problems; what is so different about the side effects for 
antiandrogen drugs? MPA, the only drug used for chemical castration in the United States, is not 
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FDA approved. Giving antiandrogen drugs to sex offenders violates the moral principle of non-
maleficence, i.e. the responsibility to avoid inflicting harm. 
Chemical castration is often viewed as more palatable than surgical castration because it 
is a reversible procedure. Conversely, though, the side effects of the drug may not be reversible 
even after the medication is discontinued. Because the side effects are so unpleasant or 
jeopardizing to their health, many patients do not continue with treatment. Thus, longitudinal 
studies of the side effects are incomplete, because those with the severest side effects drop out. 
Other problems with empirical study of these drugs exist. Due to concerns for public 
safety, randomized, double-blind, and placebo-controlled studies are not ethically possible and 
have not been conducted. Researchers could not ethically allow known offenders to be released 
without providing some sort of treatment. Without a placebo group, measurements of 
effectiveness are not entirely accurate.  
Parole Board Coercion  
The practice of chemical castration using MPA and CPA severely limits the autonomy of 
patients undergoing the treatment. Criminals necessarily forfeit some rights to freedom, but sex 
offenders up for parole in states which offer chemical castration are forced to accept medical 
treatment or return to jail. In California, Michigan and Florida, taking MPA is a mandatory 
condition of release for repeat offenders and for  particularly violent first time offenders. If 
prisoners choose not to undergo MPA treatment, they can opt for either surgical castration or life 
imprisonment (Carpenter, 1998; Harrison, 2007). Some may claim it is sufficient that prisoners 
have a choice about whether to accept treatment, but when prisoners are forced to choose 
between the exercise of their right to freedom and their right to health and bodily integrity, it can 
hardly be claimed to be a free choice. 
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In the UK, Canada, Germany, Austria and other countries which offer pharmacotherapy 
for sex offenders, participation is voluntary (Harrison, 2008). Harrison (2008) suggests that those 
eligible for chemical castration meet with a mental health professional to determine that they are 
not acting out of a desire to punish themselves  and that they are able to consent to the risks. If 
chemical castration is to be offered, this seems to be a necessary precaution. However, 
understanding the risks and freely consenting to the risks are two different things. Maletzky 
(1980) found no significant difference between court-referred and self-referred pedophiles in 
terms of compliance, attendance and recidivism rates. This suggests that even if MPA or CPA 
treatment is not officially linked to parole, offenders will opt to participate because they hope to 
impress the parole board rather than a desire to suppress deviant thoughts. Their ability to 
consent to the medical procedure is compromised by the potential outcomes of participation 
which could lead to a drastic change in lifestyle. 
Equal Access to Drugs 
 After discussing the element of coercion in chemical castration, the issue of distributive 
justice may seem incongruent. Yet, Harrison (2008) notes that there are some outside the 
criminal justice system seeking to take antiandrogen drugs. As previously noted in this paper, a 
high number of sexual assaults are unreported and offenders never prosecuted. Currently, 
antiandrogen treatments are only available to those in the criminal justice system; that is, those 
who have legal convictions and, for countries where programs are voluntary, meet referral 
criteria. Should those who recognize that they have a problem and threaten public safety be 
denied treatment just because they do not have a criminal record?  
 Those outside the criminal justice system would be free of coercion and presumably be 
more aware of the risks if they had to do their own research about the subject. Also those who 
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really wanted to take these drugs might attempt to find the medication by any means and so it 
would be better to have a qualified medical professional administer the drug. It would be 
unethical to jeopardize public safety and the patient safety by denying them treatment; however, 
appropriate protocols should be set up to determine whether the patient is able to consent to the 
course of treatment.  
Reinforcement of Sexual Assault Myths 
 An arguably less weighty moral objection to the use of antiandrogens to chemically 
castrate is the possible reinforcement of sexual assault myths. By stating that there is a cure for 
offenders that is only available to a subset of offenders effectively confirms the stereotypical 
image of a sex offender and sexual assault. There is no typical assault, and survivors of crimes 
that are not like the majority of cases may feel marginalized. These drugs are only available to 
male offenders, despite the fact that female sex offenders, while not as prevalent, exist. A parolee 
taking these medications may not be able to maintain an erection, but this does not preclude 
touching or the use of a foreign object. Further, while these drugs limit sexual drive and 
fantasies, there is some evidence that these drugs do not significantly reduce violent tendencies 
and offenders could commit other, related crimes.   
Treatment or Punishment and Issues of Proportional Punishment 
Baker (1984) correctly notes that there is a difference between preventing criminal 
offending and preventing all sexual activity. MPA and CPA limit criminal offending in some 
patients, but at the cost of limiting all sexual activity. By subjecting prisoners to a treatment 
which exceeds what is needed for the cure, we further violate the principle of non-maleficence.  
The etiology and pathophysiology of paraphilias are unclear. The neurobiological basis of 
sexual arousal, drive and behavior is extremely complex. Different sexual processes occur in the 
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central nervous system, the peripheral nerves and the primary and secondary genital organs 
(Meston & Frohlich, 2000). Deviant sexual behaviors could be caused by brain chemistry, brain 
abnormality, learned behaviors or some unknown mechanism. The drugs used to chemically 
castrate sex offenders reduce arousal and sex drive in all contexts, not just inappropriate ones. A 
drug which properly treated pedophilia would suppress only deviant sexual urges, but would 
allow for appropriate sexual encounters with adults. Chemical castration is threat reduction, not 
treatment. 
More complicated than the case for child molesters, who suffer from a diagnosable 
disease, is the issue of rapists with adult victims. While they may suffer from other mental 
illnesses, rapists do not receive a special DSM diagnosis. One of the proposed revisions to the 
DSM-V under review by the paraphilias subworkgroup is “Paraphilic Coercive Disorder”,  
defined as “ recurrent, and intense sexual arousal from sexual coercion, as manifested by 
fantasies, urges, or behaviors” resulting in distress or seeking “sexual stimulation from forcing 
sex on three or more non-consenting persons on separate occasions” (APA, n.d.).  But currently 
the field of psychopathology does not recognize those who commit rape as mentally ill based on 
the act alone. (The inclusion of paraphilic coercive disorder is morally troubling in and of itself, 
both because of the implications for the criminal justice system and the potential financial benefit 
to pharmaceuticals. If this is defined as a disorder, they will be able to market SSRIs for this 
use.) Medication for something that is not a disease cannot really be called treatment. If these 
medications are not treatments, then we must name them punishment. Just as treatment should 
not exceed cure, punishment should not exceed the crime.   
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Conclusions – What should be done? 
 The ethical dilemma posed by the possibility of castrating repeat sex offenders is, in 
essence, a question of the opposing needs of public safety and personal rights. Granted, felons do 
lose certain rights as citizens; for instance, they are not allowed to bear arms. In the interest of 
public safety, those who are incarcerated lose the exercise of their right to personal freedom for 
the duration of their prison sentence. 
 However, chemical castration represents a policy nominally in the interest of public 
safety. It compromises the rights of the all in compromising the rights of the few. We do not 
need to go into the hypothetical to understand how this medical technology may be used; we may 
look to history for example. Encouraged by the eugenics movement, several U.S. states passed 
laws allowing for the involuntary sterilization of mental patients (Sofair & Kaldijian, 2000). Nazi 
Germany also embraced the eugenics movement and performed mass sterilizations of people 
with schizophrenia, epilepsy, alcoholism, manic depression, hereditary deafness or blindness, 
severe hereditary physical deformity, Huntington chorea, and congenital feeblemindedness. 
Feeblemindedness, a diagnosis based on the discretion of the physician, targeted race (Sofair & 
Kaldijian, 2000). Eugenic sterilization has largely fallen out of favor due to its association with 
the massive human rights violations perpetrated by the Nazis, but if we allow the chemical 
castration of sex offenders, we open the door to eugenics once again – how can we determine 
who is deserving of castration? 
In addition to the potential costs to society, the costs to the individual undergoing 
chemical castration are excessively high. A drug which is not approved in the United States for 
its on-label use is approved for an off-label, experimental use on felons. The use of MPA and 
CPA violate prisoner rights to health and human dignity. A violation of these rights is 
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disproportional in comparison to what is needed to provide security to society. Lastly, MPA and 
CPA do not ensure full security because of the unclear effectiveness of the drug and the 
possibility of non-compliance.  
For these reasons, I find that the use of MPA and CPA for chemical castration of sex 
offenders to be unethical. 
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